Checking Out the Fundamental Data for ZIOPHARM Oncology, Inc. (ZIOP)

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) trade is getting exciting but lets take a deeper look whether it is as good a moment. Now trading with a market value of 486.03M, the company has a mix of catalysts and obstacles that spring from the nature of its operations. As the day-to-day narrative ebbs and flows for this company, it is more important than ever to step back and get a bird’s eye view of the fundamental reality under the surface of this story.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For ZIOP, the company currently has 51.5 million of cash on the books. The trend over time is important to note. In this case, the company’s debt has been growing. The company also has 87.46 million in total assets, balanced by 61.57 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

ZIOPHARM Oncology, Inc. (ZIOP) saw -19.11 million in free cash flow last quarter, representing a quarterly net change in cash of -19.84 million. Perhaps most importantly where cash movements are concerned, the company saw about -18.96 million in net operating cash flow.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 146,000 in total revenues. That represents a quarterly year/year change in revenues of -1.00 in sequential terms, the ZIOP saw sales decline by -1.00.

But what about the bottom line? After all, that’s what really matters in the end. ZIOPHARM Oncology, Inc. (ZIOP) is intriguing when broken down to its core data. For shareholders, given the total diluted outstanding shares of 140.85 million, this means overall earnings per share of -0.15. Note, this compares with a consensus analyst forecast of -0.13 in earnings per share for its next fiscal quarterly report.

Is ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Valuation Attractive

Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about -0.41 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 9,999. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on ZIOPHARM Oncology, Inc..

Previous ArticleNext Article

Related Post

For Emerson Electric Co. (EMR), It May Be As Good ... Emerson Electric Co. (NYSE:EMR) is in the highlights and many would want to know whether now might be a good time for it to present much upside. Now t...
Colgate-Palmolive Company (CL) Forming A Pattern O... Colgate-Palmolive Company (NYSE:CL) is in the highlights and many would want to know whether now might be a good time for it to present much upside. N...
Comparing ConocoPhillips (COP) and Enterprise Prod... ConocoPhillips (NYSE:COP) and Enterprise Products Partners L.P. (NYSE:EPD) are the two most active stocks in the Independent Oil & Gas industry ba...
Technical Indicators Turn Indifferent For HCP, Inc... HCP, Inc. (NYSE:HCP) gained 1.09% in yesterday’s session, going up from its prior closing price of $26.71 to $27.00. The price has fallen in 7 of the ...
Why You Should Want To Trade QEP Resources, Inc. (... QEP Resources, Inc. (NYSE:QEP) is on our radar right now but there could still be some opportunities on the horizon. Now trading with a market value o...